Insights

  • Home
  • Insights
  • 2023 False Claims Act Enforcement in Health Care and Life Sciences, Part III

Share

2023 False Claims Act Enforcement in Health Care and Life Sciences Part 3

2023 False Claims Act Enforcement in Health Care and Life Sciences, Part III

June 17, 2024 White Paper

In February 2024, the Department of Justice ("DOJ") announced the results of its 2023 False Claims Act ("FCA") enforcement efforts. Through those efforts, it obtained more than $2.6 billion in overall recoveries, and of that amount, $1.8 billion came from health care and life sciences ("HCLS") stakeholders alone.  

Jones Day is issuing the third installment of its three-part White Paper: "2023 False Claims Act Enforcement in Health Care and Life Sciences." In Part I of the White Paper, Jones Day provides an overview of DOJ's FCA enforcement in the HCLS industry during 2023, how that enforcement differed from previous years in terms of monetary recoveries, DOJ's case mix, as well as the evolution of DOJ's priorities and judicial decisions impacting this area. 

In Part II of the White Paper, we cover the major trends identified in Part I in more detail, discussing 2023 FCA matters involving the Anti-Kickback Statute and Stark Law, Medicare Advantage (Part C), cybersecurity, pandemic fraud, as well as the crescendo of public statements from federal regulators about private equity and corporate ownership in the health care and life sciences space.  

Now, in Part III, we provide in-depth discussions of key FCA developments from the bench, including Schutte, Polansky, causation, and other topics.

Read the White Paper: "2023 False Claims Act Enforcement in Health Care and Life Sciences, Part III (View from the Bench)"

Read the White Paper: "2023 False Claims Act Enforcement in Health Care and Life Sciences, Part II (2023 Trends and Case Details)"

Read the White Paper: "2023 False Claims Act Enforcement in Health Care and Life Sciences, Part I (Overview") 

Insights by Jones Day should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request permission to reprint or reuse any of our Insights, please use our “Contact Us” form, which can be found on our website at www.jonesday.com. This Insight is not intended to create, and neither publication nor receipt of it constitutes, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
Contributors
You May Also Be Interested In

2023 False Claims Act Enforcement in Health Care and Life Sciences, Part I

2023 False Claims Act Enforcement in Health Care and Life Sciences, Part II

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.